Regulatory Consulting for Pharma: FDA Submission Support, REMS, and Post-Market Surveillance

TL;DR

Regulatory consulting for pharma covers FDA and ex-US health authority strategy from pre-IND through post-market: IND, BLA, NDA, and sBLA submissions; REMS design and operations; labeling negotiation; post-marketing commitments; pharmacovigilance; and advisory committee prep. The market splits into four tiers. Scale CROs (IQVIA, Parexel, ICON, Labcorp, Syneos Regulatory) offer integrated throughput and global reach. Boutiques (Halloran, Biologics Consulting, Greenleaf, Lachman, PharmaLex, Cato, Voisin) compete on ex-FDA talent and senior strategic judgment. FDA law firms (Hyman Phelps, King & Spalding, Covington, Ropes & Gray) handle legally consequential matters and adcom prep. Cell and gene therapy regulatory concentrates in a handful of boutiques with CBER depth. Choosing a partner depends on modality, stage, geography, and whether the question is scientific, operational, or legal.

---

Why Regulatory Consulting Is Under-Covered

Regulatory is one of the highest-stakes functions in biopharma. A single missed deficiency in an IND or BLA module can delay approval by months and destroy launch economics. Yet the market for regulatory consulting is one of the most opaque in pharma services: day rates are rarely published, firm scope is often bundled with clinical or quality, and the difference between a scale CRO and a boutique is not obvious to a first-time biotech founder. This guide maps the vendor landscape, the services inside a regulatory engagement, typical pricing, and a decision framework for matching firm to situation.

---

Regulatory Consulting Scope

A mature regulatory engagement can span every phase from candidate selection through loss of exclusivity. Core workstreams:

• Pre-IND and pre-submission strategy. Target product profile definition, CMC and preclinical gap analysis, pre-IND meeting package assembly, briefing documents, FDA meeting type selection (Type A, B, C, D), indication scoping against precedent.
• IND preparation and maintenance. IND authoring across Modules 1-5, protocol regulatory review, 30-day clock management, clinical hold response, annual reports, protocol amendments, IND transfer in licensing and M&A.
• BLA / NDA submission. eCTD authoring and publishing across all five CTD modules, cross-functional compilation of CMC, nonclinical, clinical, and labeling content, SPL, validation and gateway submission, Information Request response, CSR integration, ISS/ISE.
• FDA meeting preparation. Type B pre-IND, end-of-Phase 1, end-of-Phase 2, pre-BLA, pre-NDA meetings. Type C targeted scientific questions, Type A dispute resolution, briefing document strategy, mock sessions, minute negotiation.
• Expedited and designation pathways. Orphan Drug Designation, Fast Track, Breakthrough Therapy, Accelerated Approval (Subpart H / Subpart E), Priority Review Vouchers, RMAT, Rare Pediatric Disease. EMA PRIME and Conditional Marketing Authorization.
• REMS design and maintenance. REMS necessity analysis, ETASU proportionality, REMS document authoring, HCS versus patient versus certification-based architecture, REMS vendor coordination (registries, call centers, certification platforms), post-approval assessments, modification and discontinuation strategy.
• Labeling and prescribing information. Draft label authoring, indication statement negotiation, boxed warning positioning, drug interaction, pregnancy, and pediatric labeling, fair balance, ongoing safety labeling changes.
• Post-market and pharmacovigilance. PMC and PMR tracking, DSUR, PADER, PBRER and PSUR, aggregate safety reporting across regions, ICSR processing, signal detection, RMP updates.
• Advisory committee preparation. Adcom briefing books, mock adcom rehearsal, expert witness and KOL panel development, voting member background analysis, open public hearing strategy.
• OTC and companion diagnostics. OTC monograph and NDA conversion strategy. Companion Dx co-development with parallel FDA-CDRH coordination, 510(k), de novo, and PMA pathway integration.
• Global parallel strategy. EMA centralized procedure, MHRA (UK post-Brexit), PMDA (Japan), NMPA (China) including MRCT acceptability, Health Canada, ANVISA, WHO prequalification.

---

Firm Tiers

The regulatory consulting market breaks into four distinct tiers, each with different economics and ideal-customer profile.

Tier 1: Scale CROs With Integrated Regulatory Service Lines

These firms bundle regulatory into broader clinical development platforms. They win on scale, throughput, global footprint, and integration with clinical and pharmacovigilance services.

• IQVIA Regulatory Consulting. 3,300+ regulatory affairs professionals across 65+ global locations per IQVIA disclosures. End-to-end support across small molecule, biologics, biosimilars, vaccines, CGT, and combination products. Deepest CRO data moat via MIDAS, NPA, and RWE assets. Well-suited to large-pharma portfolio work and global filings.
• Parexel Regulatory Consulting. Regulatory practice traces to the firm’s 1982 origins advising Japanese and German firms on FDA navigation. One of the longest-tenured regulatory consulting practices. Strong meeting management, submission authoring, and ex-regulator advisory network.
• ICON Regulatory. Early-phase through post-approval, with a clinical-regulatory integrated model post-PRA Health Sciences acquisition. Strength in biologics and complex combination products.
• Labcorp Drug Development. Integrated early-development regulatory combined with bioanalytical, nonclinical, and clinical services. Differentiated where preclinical-to-Phase 1 continuity matters.
• Syneos Health Regulatory. Integrated clinical-commercial-regulatory model. Strong for sponsors wanting a single CRO for trial execution plus regulatory, though regulatory is smaller as a share of revenue.

Tier 2: Mid-Size Specialists

• Premier Research. Regulatory strategy embedded within a rare-disease specialty CRO. Strong orphan and pediatric track record.
• Medpace Regulatory. Integrated function inside Medpace’s full-service model. Favored for mid-size biotech running full-service trials.
• PPD (Thermo Fisher) Regulatory. Regulatory inside Thermo Fisher’s clinical research services platform. Scale comparable to ICON or Parexel, less independently branded.

Tier 3: Boutique Regulatory Firms (Pure-Play Strategic)

Boutiques are where ex-FDA talent concentrates. These firms compete on senior judgment, reviewer relationships, and strategic depth rather than operational scale. Default first call for pre-commercial biotech, first-in-human programs, rare disease, and CGT.

• Halloran Consulting Group. Founded 1998 by Laurie Halloran; offices in Boston and San Diego. Collaborates across CDER, CBER, and CDRH. Regulatory readiness assessments, roadmaps, FDA meeting strategy. Deep biotech bench. A PLG company.
• Biologics Consulting Group. Multidisciplinary regulatory strategy and operations for biologics, pharmaceuticals, devices, and combination products. Deep ex-CBER bench. Strong CGT and biologics track record.
• Greenleaf Health. Led by senior ex-FDA officials, including former CBER Director Dr. Karen Midthun. Notable additions of former CBER Office of Tissues and Advanced Therapies (OTAT) leadership. Distinctive CGT team.
• Lachman Consultants. Founded 1978. Ex-senior FDA managers, reviewers, and investigators. Strong in compliance, mock FDA audits, generics and ANDAs, and CMC.
• PharmaLex (a Cencora company). 60+ offices in 32 countries; 1,600+ clients. Strong ex-US breadth (EMA, MHRA, PMDA, NMPA) and large global pharmacovigilance operations. Post-2022 Cencora acquisition, increasingly integrated with Cencora’s commercial and specialty platform.
• Cato Research. Full-service regulatory and clinical consulting with particular depth in rare disease and orphan.
• Voisin Consulting Life Sciences. Paris-headquartered boutique. Strong EMA and global regulatory, market access, and pharmacovigilance. Natural choice when European sequence leads US.

Tier 4: FDA-Focused Law Firms

Law firms are engaged when the question is legally consequential or requires attorney-client privilege: advisory committees, formal dispute resolution, citizen petitions, Warning Letter and 483 response, controlled substance scheduling, promotional review disputes, litigation, and transactional FDA diligence.

• Hyman, Phelps & McNamara. Founded 1980. Largest US law firm dedicated exclusively to FDA work. Deep ex-FDA attorney network. Author of the FDA Law Blog. Covers drugs, biologics, devices, dietary supplements, OTC, cosmetics, controlled substances, food.
• King & Spalding Life Sciences. FDA regulatory, enforcement defense, transactional FDA diligence. Deep adcom bench.
• Covington & Burling. FDA regulatory, drug pricing, 340B, healthcare fraud and abuse, enforcement. Global pharma client base.
• Ropes & Gray Life Sciences. FDA regulatory, controlled substances, enforcement, life sciences M&A with embedded FDA diligence.
• Latham & Watkins Life Sciences. Transactional FDA regulatory, enforcement, dispute resolution.

Cell and Gene Therapy Specialization

CGT regulatory concentrates in a handful of firms because CBER processes differ from CDER, and the scientific complexity of autologous and allogeneic cell products, AAV and lentiviral vectors, and in vivo editing requires specialist judgment. Halloran, Biologics Consulting, Greenleaf, and PharmaLex CGT are the primary destinations. Trinity Life Sciences provides ad hoc regulatory support adjacent to CGT commercialization engagements, though Trinity is primarily commercial and market access. Certara contributes model-informed drug development (MIDD) and regulatory submissions support, particularly relevant to CGT dose justification and complex PK/PD submissions.

---

Head-to-Head Comparison

The following matrix is a simplified view of how firms position across core dimensions. Engagement sizes and day rates are industry benchmark ranges rather than quoted pricing.

Firm	Scope	Typical engagement	Day rate (senior)	FDA meeting experience	Specialty depth	Best-for
IQVIA Regulatory	Full-stack	$1M-5M+	$400-600/hr	Very high	All modalities; global	Large pharma global portfolio
Parexel Regulatory	Full-stack	$500K-3M	$400-600/hr	Very high	All modalities	Mid-large pharma, global filings
ICON Regulatory	Full-stack	$500K-3M	$400-600/hr	Very high	Biologics, combination	Integrated clinical-regulatory
Labcorp Early Dev	Preclinical to P1 focus	$300K-2M	$350-550/hr	High	Small molecule, biologics	Preclinical-to-IND continuity
Syneos Regulatory	Full-stack	$300K-2M	$350-550/hr	High	Commercial-adjacent	Integrated clinical-commercial-reg
Halloran	Strategic + tactical	$100K-750K	$400-650/hr	High (ex-FDA network)	CGT, biologics, rare	Pre-commercial biotech
Biologics Consulting	Strategic + tactical	$100K-750K	$400-650/hr	Very high (ex-CBER)	Biologics, CGT, devices	CBER-heavy programs
Greenleaf Health	Strategic advisory	$150K-1M	$500-800/hr	Very high (ex-senior FDA)	CGT, biologics	Senior FDA advisory, CGT
Lachman	Strategic + compliance	$100K-750K	$400-650/hr	High (ex-FDA)	Generics, CMC, compliance	ANDA, mock audits, CMC
PharmaLex	Full-stack global	$200K-2M	$350-550/hr	High	Global, PVG-heavy	Ex-US and global PVG
Cato Research	Full-stack	$150K-1M	$400-600/hr	High	Rare disease, orphan	RDH programs
Voisin Consulting	Full-stack global	$150K-1M	$400-600/hr	High (EMA-lean)	EMA, global	Europe-first filings
Hyman Phelps	Legal + advisory	$200K-2M	$700-1,200/hr	Very high	All; litigation	Legally consequential matters
King & Spalding	Legal + advisory	$250K-2M	$800-1,200/hr	Very high	All; litigation	Adcom, enforcement
Covington & Burling	Legal + advisory	$250K-2M	$800-1,200/hr	Very high	Pricing, 340B, FDA	Pricing + FDA-adjacent

---

Pricing

Regulatory consulting pricing is more opaque than most pharma services categories because engagements are highly customized, talent-intensive, and often scoped by milestone rather than hours. The ranges below are industry benchmarks drawn from sponsor-side RFP experience and are not fixed quotes.

Day Rates and Engagement Sizes by Tier

• Scale CROs. Blended rates of $300-500/hr across seniority mix. Senior regulatory directors and former-FDA advisors can exceed $600/hr. Engagements of $500K to $5M+ depending on scope (strategy-only, single submission, multi-region filings, functional outsourcing).
• Boutiques (pure regulatory). Senior partner and principal rates typically $350-600/hr. Full engagements of $100K to $750K for most biotech projects, with strategic retainers scaling to $1M+ for multi-program platform companies.
• FDA law firms. Senior attorney rates $600-1,200/hr, with top-tier adcom and enforcement counsel at the upper end. Engagements of $200K to $2M depending on scope. Dispute resolution, advisory committee preparation, and Warning Letter response can exceed $2M.

Workstream-Specific Benchmarks

• eCTD BLA or NDA submission. $500K-2M all-in (authoring, publishing, gateway submission, IR response). Complex biologics and combination products at the upper end.
• IND preparation. $150K-500K for a straightforward first IND; more for complex CGT or combination products.
• REMS design. $200K-500K initial, plus $100-300K/yr maintenance and vendor coordination. Complex shared-system REMS exceeds this.
• Pharmacovigilance outsourcing. $300K-3M+/yr depending on case volume, products, geographies, and whether scope is full case processing or aggregate reporting only.
• FDA meeting preparation. $50K-250K per meeting; higher for pre-BLA and advisory committee.
• Adcom preparation. $1-5M all-in when combining law firm, regulatory consulting, mock adcom, and expert witness prep.
• Due diligence (M&A regulatory). $50K-500K per target depending on portfolio and data room depth.

Figures are ranges that move with modality, therapeutic area, indication count, and geographic scope. First-time biotech sponsors should assume the midpoint and plan for 20-30% contingency.

---

Engagement Types

Sponsors engage regulatory consultancies under five typical contracting structures:

• Strategic (pre-IND through approval). Multi-year advisory plus operational support spanning IND, pivotal design, pre-BLA, BLA, and launch readiness. A senior partner typically acts as the sponsor’s de facto Head of Regulatory. Common at boutiques for pre-commercial biotech without an in-house regulatory head.
• Tactical (single submission). A single IND, BLA, sBLA, annual report, or post-approval supplement. Scoped by deliverable. Common at scale CROs and boutiques.
• Functional Service Provision (FSP). The firm operates an entire function on the sponsor’s behalf: regulatory affairs, regulatory operations, pharmacovigilance, or medical writing. Dominant at scale CROs and at PharmaLex for PVG. Retainer-based and often multi-year.
• Senior advisory (ex-FDA bench). Access to senior ex-FDA reviewers and former center leadership for strategy, adcom prep, and dispute resolution. Common at Greenleaf, Halloran, Biologics Consulting, Hyman Phelps, and King & Spalding. Day rates at the top of the market.
• Due diligence. Regulatory review for M&A, licensing, and financing. Typically 2-6 weeks, flat-fee or milestone-based. Law firms dominate transactions requiring attorney-client privilege.

---

Ex-FDA Talent Dynamics

The value of ex-FDA staff is not theoretical. Former reviewers and center leadership bring three practical advantages: pattern recognition on what makes a submission approvable in a specific division, current understanding of review team preferences (which evolve year to year), and the ability to anticipate questions before the Information Request arrives.

Ex-FDA talent concentrates at Halloran (CGT and biologics branch and division leadership), Biologics Consulting (large CBER alumni base in vaccines, blood products, CGT), Greenleaf Health (former CBER Director Karen Midthun, ex-OTAT leadership), Lachman Consultants (ex-FDA CMC managers, reviewers, investigators), Hyman Phelps (ex-FDA attorneys across drug, biologics, device, food law), and King & Spalding (ex-FDA Office of Chief Counsel attorneys). For pre-commercial biotech facing a contentious FDA review or advisory committee, a blended team of a boutique regulatory firm plus an FDA law firm is often more valuable than a scale CRO, regardless of price.

---

Choose X When

• First-launch biotech, pre-IND. Halloran, Greenleaf, or Biologics Consulting. Senior strategic judgment and ex-FDA access matter more than throughput. Typical engagement $150-500K through IND.
• Large pharma sBLA or multi-region filings. IQVIA, Parexel, or ICON. Throughput, global footprint, and integrated clinical-regulatory operations. Engagement $1-5M+ annually.
• Rare disease or orphan programs. Halloran, Biologics Consulting, or Cato Research. Rare disease regulatory is its own specialty with distinct precedent (accelerated approval, natural history, surrogate endpoints, small N). Ex-FDA rare disease reviewers are disproportionately valuable. See the rare disease launch vendor playbook.
• Cell and gene therapy. Halloran, Biologics Consulting, or Greenleaf. CBER and OTAT fluency is essential. CGT specialization is thin across the scale CRO tier, which is why sponsors pair a scale CRO for clinical ops with a boutique for regulatory. See CGT commercialization services.
• Advisory committee prep or litigation risk. Hyman Phelps or King & Spalding. Attorney-client privilege, ex-FDA counsel, and adcom mock capabilities. Typically paired with Greenleaf, Halloran, or Biologics Consulting on the scientific workstream.
• Global filings (EMA, MHRA, PMDA, NMPA). PharmaLex, Voisin Consulting, or Parexel. PharmaLex’s 60+ office footprint and Voisin’s EMA depth are decisive for Europe-first or parallel global filings.
• ANDA, CMC compliance, mock FDA audit. Lachman Consultants. Distinctive specialization in generics, CMC, and inspection readiness.
• FDA pricing, promotional review, 340B-adjacent. Covington & Burling. Often paired with Guidehouse for CMS policy and commercial implementation.

---

Post-Launch Regulatory Obligations

Approval is not the endpoint. Post-launch regulatory scope typically grows rather than shrinks, and the vendor footprint shifts from project-based to retainer.

• REMS execution and vendor coordination. Sponsors of approved REMS products own prescriber certification, patient enrollment, pharmacy certification, training modules, registry data collection, and periodic REMS assessments. Regulatory consultancies typically own REMS strategy and the FDA interface while dedicated REMS operators (Eversana and hub services vendors) run operations. See the pharma services overview for adjacent hub and REMS operational vendors.
• Labeling updates. PI changes can be sponsor-driven or FDA-driven (Safety Labeling Change letter) and trigger sBLAs, Prior Approval Supplements, CBE-0, CBE-30, or Annual Report filings depending on change type.
• Pharmacovigilance reporting cadence. Expedited 15-day IND safety reports and post-marketing 15-day reports. PADER quarterly in Years 1-3 then annual. DSUR annually for products still in development. PBRER / PSUR periodically post-approval. RMP updates as signals emerge. Ex-US regions have parallel but non-identical requirements.
• PMC and PMR tracking. FDA-mandated post-approval studies with milestone and reporting obligations. Failure can trigger enforcement. Common scopes: pediatric studies under PREA, long-term safety, confirmatory studies for accelerated approval.
• Life-cycle submissions. Annual reports, CMC changes, new indications (sBLA/sNDA), pediatric extrapolation, biosimilar references, patent and exclusivity filings. These workstreams dominate regulatory spend for approved products and are where scale CRO functional outsourcing is most compelling.

---

How This Category Fits the Broader Vendor Stack

Regulatory consulting overlaps meaningfully with adjacent categories covered elsewhere on Rx Almanac:

• Market access consulting shapes evidence requirements that regulatory strategy must satisfy.
• Real-world evidence vendors generate post-market evidence that drives label expansions and PMR completion.
• Specialty pharmacies operationalize REMS and risk mitigation at the point of dispense.
• Medical affairs and MSL outsourcing handles scientific exchange workstreams adjacent to regulatory submissions and advisory committee engagement.

Regulatory is rarely the only decision in the vendor stack, but it is frequently the one with the largest downside if the wrong partner is selected.

---

Verdict

Regulatory consulting is one of the most consequential and least transparent vendor categories in pharma services. The right firm depends on four variables: modality, stage, geography, and the nature of the question (scientific, operational, or legally consequential).

For pre-commercial biotech, default to a boutique: Halloran, Biologics Consulting Group, or Greenleaf for strategic pre-IND through BLA. For large pharma portfolio work, default to a scale CRO: IQVIA, Parexel, or ICON for integrated global throughput. For legally consequential matters, advisory committees, or enforcement, default to an FDA law firm: Hyman Phelps is the largest dedicated FDA firm; King & Spalding, Covington, and Ropes & Gray are the other leading options.

Sponsors who get this right typically use two or three firms concurrently: a boutique for senior strategy, a scale CRO or PharmaLex for operational regulatory and pharmacovigilance, and an FDA law firm for adcom prep and high-risk correspondence. Single-firm regulatory stacks are rare outside the largest pharma clients. The combined cost is high, but the downside of a missed deficiency, a failed adcom, or a REMS misstep is higher by orders of magnitude.